HONG KONG, Nov. 7, 2025 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926.HK) is excited to announce that the final Overall Survival (OS) analysis results from the HARMONi-A study, a Phase III study evaluating ...
247 patients (mean age 14.3±7.6 years) were enrolled from study sites in North America, Europe, and Australia, with a median fenfluramine exposure of 364 days (range: 19–537) and a mean daily dose of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results